| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
RS-127445 was discovered to be 1,000 times more selective for the 5-HT2B receptor than many other receptor and ion channel binding sites, with a nanomolar affinity for this receptor (pKi=9.5±0.1). When the human recombinant 5-HT2B receptor is expressed in CHO-K1 cells, RS-127445 effectively replaces [3H]-5-HT. For the 5-HT2B receptor, RS-127445 has an affinity (pKi value) of 9.5±0.1 (n=9). While having affinity for human recombinant 5-HT2A, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 receptors, RS-127445 is selective for 5-HT2B receptors (5-HT1A receptor in rat) The amount of 5-HT1B/D receptors in the meninges, the caudate nucleus of cows, and the monoamine absorption sites in rabbit platelets has been reduced by almost 1000 times. Strong inhibition of 5-HT (10 nM) by RS-127445 resulted in an elevation of intracellular calcium concentration in HEK-293 cells expressing 5-HT2B receptors (pIC50 of 10.4±0.1). RS-127445 efficiently inhibited the production of phosphoinositides (pKB=9.5±0.1) and a rise in intracellular calcium (pIC10=10.4±0.1) generated by 5-HT in cells expressing human recombinant 5-HT2B receptor. Additionally, RS-127445 prevents (±)α-methyl-5-HT-mediated rat jugular vein relaxation (pA2=9.9±0.3) and 5-HT-induced rat gastric fundus contraction in vitro (pA2B=9.5±1.1)[1].
|
|---|---|
| ln Vivo |
RS-127445 was 14% and 60% more bioavailable in rats when administered orally compared to when administered intraperitoneally. It is anticipated that plasma concentrations from the intraperitoneal injection of RS-127445 (5 mg/kg) will fully saturate accessible 5-HT2B receptors for a minimum of 4 hours. Oral, intraperitoneal, and intravenous administration of RS-127445 (5 mg/kg) were used on rats. The first time point assessed following intravenous and intraperitoneal treatment (0.08 hours) and the 0.25 hours following oral administration are when plasma concentrations peak the fastest. The predicted final elimination half-life of RS-127445 is 1.7 hours, after which it is removed from plasma. About 14% and 62% of RS-127445's bioavailability when given intravenously is achieved when given orally and intraperitoneally, respectively. In terms of bioavailability, RS-127445 (5 mg/kg) is 14% oral and 60% intraperitoneal [1]. Significant reductions in fecal production were observed with RS-127445 (1-30 mg/kg) at doses of 10 and 30 mg/kg (n=6-11). RS-127445 is >98% protein-bound in the blood and brain [2].
|
| References |
|
| Molecular Formula |
C17H16N3F.HCL
|
|---|---|
| Molecular Weight |
317.78838
|
| Exact Mass |
317.11
|
| CAS # |
199864-86-3
|
| Related CAS # |
RS-127445;199864-87-4
|
| PubChem CID |
9905058
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
5.524
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
349
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MKJPYBJBPRFMHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16FN3.ClH/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13;/h3-10H,1-2H3,(H2,19,20,21);1H
|
| Chemical Name |
4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 31 mg/mL (~97.55 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1467 mL | 15.7337 mL | 31.4673 mL | |
| 5 mM | 0.6293 mL | 3.1467 mL | 6.2935 mL | |
| 10 mM | 0.3147 mL | 1.5734 mL | 3.1467 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
